Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies Inc (NQ: TSHA )

1.950 -0.515 (-20.89%)
Streaming Delayed Price Updated: 10:34 AM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?
Taysha Gene Therapies stock is down on Wednesday after the company announced a proposed public offering for TSHA shares. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The Analyst Landscape: 16 Takes On Taysha Gene Therapies
Via Benzinga
Breaking Down Taysha Gene Therapies: 16 Analysts Share Their Views
Via Benzinga
11 Analysts Assess Taysha Gene Therapies: What You Need To Know
Via Benzinga
S&P 500 Edges Higher; America's Car-Mart Shares Tumble After Q4 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
Via Benzinga
Crude Oil Rises 1%; DermTech Shares Plummet
Via Benzinga
Exposures Fossil Fuels
What's Going On With Taysha Gene Therapies Stock Tuesday?
Taysha Gene Therapies reveals promising longer-term and initial clinical data from their REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett syndrome. 
Via Benzinga
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024
TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining over 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Promising results from a Phase 1 trial led by NIH: scAAV9/JeT-GAN gene therapy shows potential benefits for giant axonal neuropathy. The therapy demonstrated safety and efficacy in children with GAN,... 
Via Benzinga
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder
Clinical data from Taysha Gene Therapies on TSHA-102, a potential gene therapy for Rett syndrome. Explore results in improved breathing, motor skills, and seizure management, paving the way for... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning! 
Via InvestorPlace
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023
TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Taysha Gene Therapies Stock Soars On FY23 Results: Here's Why
Taysha Gene Therapies shares are climbing after the company reported its fiscal year 2023 results after the bell Tuesday. The company reported fiscal year 2023 losses of 96 cents per share, compared to... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.